Biosimilars Add “Urgency” To Medicare Payment Reforms – MedPAC Commissioner
Executive Summary
Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.
You may also be interested in...
Reimbursement Briefs: Medicare Part B, PCORI Research
MedPAC will analyze alternatives for Medicare Part B to use “least costly alternative” payment method in lieu of legislative authority; OIG says Part B dispensing fees are too high; PCORI releases draft proposal on research review.
UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
Lucentis vs. Avastin Cost Debate Resurfaces With Release Of Medicare Payment Data
Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.